Table 1.
Baseline characteristics of Spirulina group and Placebo group (value are means ± SD)
| Analyzed parameters | Spirulina group (n = 25) | Placebo group (n = 25) | P 1 |
|---|---|---|---|
| Male (n) | 12 | 13 | |
| Female (n) | 13 | 12 | |
| Age (year) | 49.3 ± 8.7 | 50.2 ± 7.2 | NS |
| Time since diagnosis of hypertension (year) | 5.7 ± 2.1 | 5.6 ± 2.5 | NS |
| Medication (n) | |||
| ACEI | 12 | 11 | |
| Sartan | 2 | 4 | |
| CCB | 9 | 8 | |
| Β-bloker | 4 | 3 | |
| Diuretic | 7 | 6 | |
| BMI (kg/m2) | 33.5 ± 6.7 | 33.3 ± 6.2 | NS |
| SBP (mmHg) | 148 ± 15 | 151 ± 15 | NS |
| DBP (mmHg) | 84 ± 9 | 85. ± 9 | NS |
| Ca (mmol/L) | 3.4 ± 0.3 | 3.3 ± 0.2 | NS |
| Mg (mmol/L) | 0.8 ± 0.1 | 0.8 ± 0.1 | NS |
| Fe (μmol/L) | 16.6 ± 3.8 | 15.8 ± 2.6 | NS |
| Zn (μmol/L) | 10.0 ± 3.5 | 10.7 ± 2.5 | NS |
ACEI angiotensin-converting enzyme inhibitor, CCB calcium channel blocker, NS not statistically significant, BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, SD standard deviation
1Differences were tested using Mann-Whitney U test